Brought to you by 
SR One leads antibody company f-star’s €15mm Series B round
14 Apr 2011
Executive Summary
In what is assumed to be its Series B round, f-star GMBH (technology that adds more binding sites into full antibodies and antibody fragments) has raised €15mm ($22mm). Led by first-time backer SR One, the financing also included all existing shareholders: Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures, and MP Healthcare Venture Management. Members of SR One and TVM have joined the company’s supervisory board. The biotech will use the money on preclinical studies of its first drug candidates in preparation for IND filing. Including the Series B funding, f-star has amassed €34mm in venture capital to date.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SR One leads antibody company f-star’s €15mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice